In 1989, the British company Beecham Group merged with the U.S. Company SmithKline Beckman. What economic advantages might the two drug companies be expecting from their marriage? More generally, what economic forces underlie the ongoing process of consolidation and globalization in the world pharmaceutical industry? Consider the merger's impact in the areas of R&D, marketing, and production.